Perampanel - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for perampanel and what is the scope of patent protection?
Perampanel
is the generic ingredient in one branded drug marketed by Catalyst Pharms and is included in two NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.Perampanel has one hundred and one patent family members in thirty-three countries.
There are five drug master file entries for perampanel. Two suppliers are listed for this compound. There are three tentative approvals for this compound.
Summary for perampanel
International Patents: | 101 |
US Patents: | 2 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 2 |
Drug Master File Entries: | 5 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 59 |
Clinical Trials: | 69 |
Patent Applications: | 705 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for perampanel |
What excipients (inactive ingredients) are in perampanel? | perampanel excipients list |
DailyMed Link: | perampanel at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for perampanel
Generic Entry Dates for perampanel*:
Constraining patent/regulatory exclusivity:
Dosage:
SUSPENSION;ORAL |
Generic Entry Dates for perampanel*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for perampanel
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
National Center for PTSD | Phase 2 |
Yale University | Phase 2 |
American Foundation for Suicide Prevention | Phase 2 |
Generic filers with tentative approvals for PERAMPANEL
Applicant | Application No. | Strength | Dosage Form |
⤷ Subscribe | ⤷ Subscribe | 10MG | TABLET;ORAL |
⤷ Subscribe | ⤷ Subscribe | 8MG | TABLET;ORAL |
⤷ Subscribe | ⤷ Subscribe | 6MG | TABLET;ORAL |
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for perampanel
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
FYCOMPA | Oral Suspension | perampanel | 0.5 mg/mL | 208277 | 1 | 2022-12-20 |
FYCOMPA | Tablets | perampanel | 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg | 202834 | 2 | 2016-10-24 |
US Patents and Regulatory Information for perampanel
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Catalyst Pharms | FYCOMPA | perampanel | SUSPENSION;ORAL | 208277-001 | Apr 29, 2016 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Catalyst Pharms | FYCOMPA | perampanel | TABLET;ORAL | 202834-002 | Oct 22, 2012 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
Catalyst Pharms | FYCOMPA | perampanel | TABLET;ORAL | 202834-003 | Oct 22, 2012 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
Catalyst Pharms | FYCOMPA | perampanel | TABLET;ORAL | 202834-004 | Oct 22, 2012 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Catalyst Pharms | FYCOMPA | perampanel | TABLET;ORAL | 202834-001 | Oct 22, 2012 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Catalyst Pharms | FYCOMPA | perampanel | TABLET;ORAL | 202834-002 | Oct 22, 2012 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Catalyst Pharms | FYCOMPA | perampanel | SUSPENSION;ORAL | 208277-001 | Apr 29, 2016 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for perampanel
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Eisai GmbH | Fycompa | perampanel | EMEA/H/C/002434 Fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in adult and adolescent patients from 12 years of age with epilepsy.Fycompa is indicated for the adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy. |
Authorised | no | no | no | 2012-07-23 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for perampanel
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Denmark | 1764361 | ⤷ Subscribe | |
Spain | 2404697 | ⤷ Subscribe | |
Canada | 2412172 | COMPOSES 1,2-DIHYDROPYRIDINE, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION (1,2-DIHYDROPYRIDINE COMPOUNDS, MANUFACTURING METHOD THEREOF AND USE THEREOF) | ⤷ Subscribe |
Japan | WO2006004100 | 1,2−ジヒドロピリジン−2−オン化合物の製造方法 | ⤷ Subscribe |
European Patent Office | 1300396 | COMPOSES 1,2-DIHYDROPYRIDINE, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION (1,2-DIHYDROPYRIDINE COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF) | ⤷ Subscribe |
Hong Kong | 1104999 | ⤷ Subscribe | |
Spain | 2320973 | ⤷ Subscribe | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for perampanel
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1300396 | 12C0074 | France | ⤷ Subscribe | PRODUCT NAME: PERAMPANEL, SEL DE CELUI-CI OU HYDRATE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/12/776/001 20120723 |
1764361 | 173 5-2013 | Slovakia | ⤷ Subscribe | PRODUCT NAME: PERAMPANEL; NAT. REGISTRATION NO/DATE: EU/1/12/776/001 - EU/1/12/776/016 20120723; FIRST REGISTRATION: EU EU/1/12/776/001 - EU/1 /12/776/016 20120723 |
1300396 | 132012902109980 | Italy | ⤷ Subscribe | PRODUCT NAME: PERAMPANEL(FYCOMPA); AUTHORISATION NUMBER(S) AND DATE(S): DA EU/1/12/776/001 A EU/1/12/776/016, 20120723 |
1300396 | SPC/GB12/057 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: PERAMPANEL, OPTIONALLY IN THE FORM OF A SALT OR HYDRATE; REGISTERED: UK EU/1/12/776/001- 016 20120723 |
1300396 | C300566 | Netherlands | ⤷ Subscribe | PRODUCT NAME: PERAMPANEL, EEN ZOUT OF EEN HYDRAAT DAARVAN; REGISTRATION NO/DATE: EU/1/12/776/001 .... 016 20120723 |
1300396 | CA 2012 00052 | Denmark | ⤷ Subscribe | |
1764361 | PA2013017,C1764361 | Lithuania | ⤷ Subscribe | PRODUCT NAME: PERAMPANELUM; REGISTRATION NO/DATE: EU/1/12/776/001 - EU/1/12/776/016, 2012 07 23 EU/1/12/776/017 - EU1/12/776/023 20121029 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Perampanel Market Analysis and Financial Projection Experimental
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.